These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35712895)

  • 1. Exploring Aspartic Protease Inhibitor Binding to Design Selective Antimalarials.
    Bobrovs R; Basens EE; Drunka L; Kanepe I; Matisone S; Velins KK; Andrianov V; Leitis G; Zelencova-Gopejenko D; Rasina D; Jirgensons A; Jaudzems K
    J Chem Inf Model; 2022 Jul; 62(13):3263-3273. PubMed ID: 35712895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the flap pocket of the antimalarial target plasmepsin II: the "55 % rule" applied to enzymes.
    Zürcher M; Gottschalk T; Meyer S; Bur D; Diederich F
    ChemMedChem; 2008 Feb; 3(2):237-40. PubMed ID: 17918177
    [No Abstract]   [Full Text] [Related]  

  • 3. Exploiting Structural Dynamics To Design Open-Flap Inhibitors of Malarial Aspartic Proteases.
    Bobrovs R; Jaudzems K; Jirgensons A
    J Med Chem; 2019 Oct; 62(20):8931-8950. PubMed ID: 31062983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the Binding Pathway of Novel Nonpeptidomimetic Plasmepsin V Inhibitors.
    Bobrovs R; Drunka L; Kanepe I; Jirgensons A; Caflisch A; Salvalaglio M; Jaudzems K
    J Chem Inf Model; 2023 Nov; 63(21):6890-6899. PubMed ID: 37801405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Picomolar Inhibition of Plasmepsin V, an Essential Malaria Protease, Achieved Exploiting the Prime Region.
    Gambini L; Rizzi L; Pedretti A; Taglialatela-Scafati O; Carucci M; Pancotti A; Galli C; Read M; Giurisato E; Romeo S; Russo I
    PLoS One; 2015; 10(11):e0142509. PubMed ID: 26566224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Click Inspired Synthesis of Novel Cinchonidine Glycoconjugates as Promising Plasmepsin Inhibitors.
    Mishra N; Agrahari AK; Bose P; Singh SK; Singh AS; Tiwari VK
    Sci Rep; 2020 Feb; 10(1):3586. PubMed ID: 32108142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin.
    Hidaka K; Kimura T; Ruben AJ; Uemura T; Kamiya M; Kiso A; Okamoto T; Tsuchiya Y; Hayashi Y; Freire E; Kiso Y
    Bioorg Med Chem; 2008 Dec; 16(23):10049-60. PubMed ID: 18952439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and characterization of allophenylnorstatine-based inhibitors of plasmepsin II, an antimalarial target.
    Nezami A; Luque I; Kimura T; Kiso Y; Freire E
    Biochemistry; 2002 Feb; 41(7):2273-80. PubMed ID: 11841219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plerixafor and related macrocyclic amines are potential drug candidates in treatment of malaria by "filling the flap" region of plasmepsin enzymes.
    Abiri A
    Med Hypotheses; 2018 Sep; 118():68-73. PubMed ID: 30037618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases.
    Abdel-Rahman HM; Kimura T; Hidaka K; Kiso A; Nezami A; Freire E; Hayashi Y; Kiso Y
    Biol Chem; 2004 Nov; 385(11):1035-9. PubMed ID: 15576323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II.
    Hidaka K; Kimura T; Tsuchiya Y; Kamiya M; Ruben AJ; Freire E; Hayashi Y; Kiso Y
    Bioorg Med Chem Lett; 2007 Jun; 17(11):3048-52. PubMed ID: 17400453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrocyclic inhibitors of the malarial aspartic proteases plasmepsin I, II, and IV.
    Ersmark K; Nervall M; Gutiérrez-de-Terán H; Hamelink E; Janka LK; Clemente JC; Dunn BM; Gogoll A; Samuelsson B; Qvist J; Hallberg A
    Bioorg Med Chem; 2006 Apr; 14(7):2197-208. PubMed ID: 16307884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. alpha-Substituted norstatines as the transition-state mimic in inhibitors of multiple digestive vacuole malaria aspartic proteases.
    Orrling KM; Marzahn MR; Gutiérrez-de-Terán H; Aqvist J; Dunn BM; Larhed M
    Bioorg Med Chem; 2009 Aug; 17(16):5933-49. PubMed ID: 19635672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Azole-based non-peptidomimetic plasmepsin inhibitors.
    Kinena L; Leitis G; Kanepe-Lapsa I; Bobrovs R; Jaudzems K; Ozola V; Suna E; Jirgensons A
    Arch Pharm (Weinheim); 2018 Sep; 351(9):e1800151. PubMed ID: 30063266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New inhibitors of the malaria aspartyl proteases plasmepsin I and II.
    Dahlgren A; Kvarnström I; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B
    Bioorg Med Chem; 2003 Aug; 11(16):3423-37. PubMed ID: 12878137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insight into selectivity of peptidomimetic inhibitors with modified statine core for plasmepsin II of Plasmodium falciparum over human cathepsin D.
    Dali B; Keita M; Megnassan E; Frecer V; Miertus S
    Chem Biol Drug Des; 2012 Apr; 79(4):411-30. PubMed ID: 22129033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational inhibitor design against malaria plasmepsins.
    Bjelic S; Nervall M; Gutiérrez-de-Terán H; Ersmark K; Hallberg A; Aqvist J
    Cell Mol Life Sci; 2007 Sep; 64(17):2285-305. PubMed ID: 17585371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of potent inhibitors of Plasmodium falciparum plasmepsin II from an encoded statine combinatorial library.
    Carroll CD; Patel H; Johnson TO; Guo T; Orlowski M; He ZM; Cavallaro CL; Guo J; Oksman A; Gluzman IY; Connelly J; Chelsky D; Goldberg DE; Dolle RE
    Bioorg Med Chem Lett; 1998 Sep; 8(17):2315-20. PubMed ID: 9873534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimalarial synergy of cysteine and aspartic protease inhibitors.
    Semenov A; Olson JE; Rosenthal PJ
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2254-8. PubMed ID: 9736544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of plasmepsin inhibitor by focusing on similar structural feature with chloroquine to avoid drug-resistant mechanism of Plasmodium falciparum.
    Miura T; Hidaka K; Azai Y; Kashimoto K; Kawasaki Y; Chen SE; de Freitas RF; Freire E; Kiso Y
    Bioorg Med Chem Lett; 2014 Apr; 24(7):1698-701. PubMed ID: 24631188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.